BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Prognosis
342 results:

  • 1. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma.
    Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C
    Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses.
    Zheng Y; Wang X; Ji Q; Fang A; Song L; Xu X; Lin Y; Peng Y; Yu J; Xie L; Chen F; Li X; Zhu S; Zhang B; Zhou L; Yu C; Wang Y; Wang L; Hu H; Zhang Z; Liu B; Wu Z; Li W
    Cancer Lett; 2024 May; 589():216834. PubMed ID: 38537773
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
    Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. High-Grade Astrocytoma with Piloid Features: A Dual Institutional Review of Imaging Findings of a Novel Entity.
    Soni N; Agarwal A; Ajmera P; Mehta P; Gupta V; Vibhute M; Gubbiotti M; Mark IT; Messina SA; Mohan S; Bathla G
    AJNR Am J Neuroradiol; 2024 Apr; 45(4):468-474. PubMed ID: 38485198
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Looking through the imaging perspective: the importance of imaging necrosis in glioma diagnosis and prognostic prediction - single centre experience.
    Ma H; Zeng S; Xie D; Zeng W; Huang Y; Mazu L; Zhu N; Yang Z; Chu J; Zhao J
    Radiol Oncol; 2024 Mar; 58(1):23-32. PubMed ID: 38378035
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinical and molecular study of radiation-induced gliomas.
    Trkova K; Sumerauer D; Bubenikova A; Krskova L; Vicha A; Koblizek M; Zamecnik J; Jurasek B; Kyncl M; Malinova B; Ondrova B; Jones DTW; Sill M; Strnadova M; Stolova L; Misove A; Benes V; Zapotocky M
    Sci Rep; 2024 Feb; 14(1):3118. PubMed ID: 38326438
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.
    Liang Q; Jing H; Shao Y; Wang Y; Zhang H
    Clin Neuroradiol; 2024 Mar; 34(1):33-43. PubMed ID: 38277059
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
    Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A novel grading system combining histological grade and cdkn2a homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    Xi S; Huang Q; Zeng J
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. CD8-Lymphocytic Phenotype Significance in Primary Multiple and Familial Melanoma with Various cdkn2a Mutational Status.
    Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Bălțătescu GI; Orășanu CI; Boşoteanu M
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138255
    [No Abstract]    [Full Text] [Related]  

  • 11. Application of novel PACS-based informatics platform to identify imaging based predictors of cdkn2a allelic status in glioblastomas.
    Tillmanns N; Lost J; Tabor J; Vasandani S; Vetsa S; Marianayagam N; Yalcin K; Erson-Omay EZ; von Reppert M; Jekel L; Merkaj S; Ramakrishnan D; Avesta A; de Oliveira Santo ID; Jin L; Huttner A; Bousabarah K; Ikuta I; Lin M; Aneja S; Turowski B; Aboian M; Moliterno J
    Sci Rep; 2023 Dec; 13(1):22942. PubMed ID: 38135704
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Immunophenotypic p14 and p16 correlations with cdkn2a mutations in primary multiple and familial melanoma: An observational study.
    Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
    Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. p16 Immunohistochemistry as a Screening Tool for Homozygous cdkn2a Deletions in CNS tumors.
    Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
    Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
    Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
    Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. prognosis of cdkn2a germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
    Taibo A; Paradela S; Suanzes-Hernández J; Balboa-Barreiro V; Amado-Bouza J; Fonseca E
    Melanoma Res; 2024 Feb; 34(1):9-15. PubMed ID: 37924530
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. MiR-484 promotes the malignant progression of glioma by inhibiting cdkn2a expression.
    Gu Y; Lei H; Ma P; Chen Y
    Folia Neuropathol; 2023; 61(3):249-265. PubMed ID: 37818686
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Clinicopathological and prognostic features of subungual melanoma in situ].
    Hu J; Ren M; Cai X; Lyu JJ; Shen XX; Kong YY
    Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1006-1011. PubMed ID: 37805391
    [No Abstract]    [Full Text] [Related]  

  • 18. Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways.
    Wang S; Gu Z; Zhu L; Han Y; Yu H; Fang W; Han B
    Chin Med J (Engl); 2023 Nov; 136(22):2712-2721. PubMed ID: 37749819
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Preoperative Discrimination of cdkn2a/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI.
    Gao J; Liu Z; Pan H; Cao X; Kan Y; Wen Z; Chen S; Wen M; Zhang L
    J Magn Reson Imaging; 2024 May; 59(5):1655-1664. PubMed ID: 37555723
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A novel MRI-based deep learning networks combined with attention mechanism for predicting cdkn2a/B homozygous deletion status in IDH-mutant astrocytoma.
    Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
    Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 18.